首頁 > 市場調查報告書 > 製藥

癌症生物製劑

市場調查報告書

商品編碼

1746674

日本癌症免疫療法市場報告（按療法類型、應用、最終用戶和地區）2025-2033

Japan Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本癌症免疫療法市場規模達75.412億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到144.583億美元，2025-2033年期間的複合年成長率（CAGR）為7.2%。推動該市場發展的幾個重要因素包括癌症發生率的上升、政府的支持性項目以及醫療保險的普及。

癌症是一種以體內某些細胞不受控制地生長並擴散到各部位為特徵的疾病。其發展通常與飲酒或吸煙、不健康飲食、暴露於空氣污染、缺乏運動等因素有關。癌症患者會面臨嚴重的健康挑戰，包括焦慮、憂鬱、對死亡的恐懼、疼痛、壓力，甚至產生自殺念頭。免疫療法是一種癌症治療方法，利用抗體結合癌細胞產生的蛋白質並抑制其活性。這種方法有助於增強免疫系統識別和清除體內異常癌細胞的能力。因此，免疫療法廣泛應用於各種癌症的治療，包括肺癌、乳癌、大腸癌、黑色素瘤、攝護腺癌、頭頸癌、甲狀腺癌、腎癌、肝癌、子宮頸癌、膀胱癌、卵巢癌和皮膚癌。

日本癌症免疫治療市場趨勢：

在日本市場，若干重要因素正在積極影響癌症免疫療法產業。主要促進因素之一是全球癌症病例數量的上升，這歸因於不良飲食習慣和接觸有害物質。此外，全球民眾對多樣化癌症治療方案的認知日益提高，這也促進了市場擴張。此外，癌症免疫療法的日益普及得益於其與傳統抗腫瘤療法相比，能夠延長無惡化存活期 (PFS) 和總存活期 (OS)。醫療保險的普及性和可近性，以及醫療支出的不斷成長，為行業投資者帶來了誘人的成長前景。此外，對副作用較小的治療方法的需求日益成長，這與新型免疫療法獲批率的不斷提高相一致，並推動了市場成長。各國政府機構和非營利組織正積極推廣癌症免疫療法，並進行以癌症預防為重點的廣泛宣傳活動。最後，市場受益於癌症治療技術的持續進步，這些進步正在提高疾病管理策略的效率。這些因素共同促進了日本癌症免疫治療市場的正向成長軌跡。

日本癌症免疫治療市場細分：

治療類型見解：

單株抗體
癌症疫苗
檢查點抑制劑
免疫調節劑
其他

應用程式洞察：

肺癌
乳癌
大腸直腸癌
黑色素瘤
攝護腺癌
頭頸癌
其他

最終用戶洞察：

醫院
癌症研究中心
診所
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本癌症免疫治療市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本癌症免疫治療市場有何影響？
根據治療類型，日本癌症免疫治療市場是如何分類的？
日本癌症免疫治療市場如何按應用情況分類？
根據最終用戶，日本癌症免疫治療市場是如何分佈的？
日本癌症免疫治療市場的價值鏈分為哪些階段？
日本癌症免疫治療的關鍵促進因素和挑戰是什麼？
日本癌症免疫治療市場的結構是怎麼樣的？主要參與者是誰？
日本癌症免疫治療市場的競爭程度如何？

本報告回答的關鍵問題：

日本癌症免疫治療市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本癌症免疫治療市場有何影響？
根據治療類型，日本癌症免疫治療市場是如何分類的？
日本癌症免疫治療市場如何按應用情況分類？
根據最終用戶，日本癌症免疫治療市場是如何分佈的？
日本癌症免疫治療市場的價值鏈分為哪些階段？
日本癌症免疫治療的關鍵促進因素和挑戰是什麼？
日本癌症免疫治療市場的結構是怎麼樣的？主要參與者是誰？
日本癌症免疫治療市場的競爭程度如何？

Japan cancer immunotherapy market size reached USD 7,541.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 14,458.3 Million by 2033, exhibiting a growth rate (CAGR) of 7.2% during 2025-2033. The market is being propelled by several significant factors, including an increasing incidence of cancer cases, supportive government programs, and the widespread accessibility of medical insurance.

Cancer is a medical condition characterized by the uncontrolled growth and spread of certain cells in the body to various parts. Its development is often linked to factors such as alcohol or tobacco consumption, an unhealthy diet, exposure to air pollution, and a lack of physical activity. Individuals affected by cancer can experience significant health challenges, including feelings of anxiety, depression, fear of mortality, pain, stress, and even thoughts of suicide. Immunotherapy is an approach to cancer treatment involving the use of antibodies that bind to and inhibit the activity of proteins produced by cancer cells. This method helps strengthen the immune system's ability to identify and eliminate abnormal cancer cells within the body. Consequently, it finds widespread application in the treatment of various cancer types, including lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers.

Japan Cancer Immunotherapy Market Trends:

In the context of the Japanese market, several significant factors are positively impacting the cancer immunotherapy sector. One of the primary drivers is the rising number of cancer cases, attributed to poor dietary habits and exposure to harmful substances among individuals worldwide. Additionally, there is a growing awareness regarding diverse cancer treatment options among the global population, contributing to market expansion. Furthermore, the increasing adoption of cancer immunotherapies is driven by their ability to offer prolonged progression-free survival (PFS) and overall survival (OS) compared to traditional anti-tumor therapies. The availability and accessibility of medical insurance, alongside rising healthcare expenditure, are presenting attractive growth prospects for industry investors. Moreover, there is a growing demand for treatment approaches with fewer adverse effects, which aligns with the increasing approval of novel immunotherapies and fuels market growth. Government agencies and non-profit organizations in various countries are actively promoting the adoption of cancer immunotherapy through widespread awareness campaigns focused on cancer prevention. Lastly, the market benefits from ongoing technological advancements in cancer treatment therapies, which are enhancing the efficiency of disease management strategies. These factors collectively contribute to the positive growth trajectory of the cancer immunotherapy market in Japan.

Japan Cancer Immunotherapy Market Segmentation:

Therapy Type Insights:

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Others

Application Insights:

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Others

End User Insights:

Hospitals
Cancer Research Centers
Clinics
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cancer immunotherapy market?
What is the breakup of the Japan cancer immunotherapy market on the basis of therapy type?
What is the breakup of the Japan cancer immunotherapy market on the basis of application?
What is the breakup of the Japan cancer immunotherapy market on the basis of end user?
What are the various stages in the value chain of the Japan cancer immunotherapy market?
What are the key driving factors and challenges in the Japan cancer immunotherapy?
What is the structure of the Japan cancer immunotherapy market and who are the key players?
What is the degree of competition in the Japan cancer immunotherapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Immunotherapy Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cancer Immunotherapy Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Cancer Immunotherapy Market - Breakup by Therapy Type

6.1 Monoclonal Antibodies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Cancer Vaccines
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Checkpoint Inhibitors
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Immunomodulators
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2019-2024)
- 6.5.2 Market Forecast (2025-2033)

7 Japan Cancer Immunotherapy Market - Breakup by Application

7.1 Lung Cancer
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Breast Cancer
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Colorectal Cancer
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Melanoma
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Prostate Cancer
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Head and Neck Cancer
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Cancer Immunotherapy Market - Breakup by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Cancer Research Centers
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Clinics
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Others
- 8.4.1 Historical and Current Market Trends (2019-2024)
- 8.4.2 Market Forecast (2025-2033)

9 Japan Cancer Immunotherapy Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Services Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Services Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Services Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Services Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Services Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Cancer Immunotherapy Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis